|
مقاله
|
Abstract
|
|
|
|
Title:
|
Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) Combined with Bevacizumab versus Bevacizumab Monotherapy for Diabetic Macular Edema; a Randomized Clinical Trial
|
|
Author(s):
|
Ramin Nourinia, Hamid Ahmadieh, Ali Hafezi-moghadam
|
|
Presentation Type:
|
Oral
|
|
Subject:
|
Posterior Segment and Uveitis
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Ramin Nourinia
|
|
Affiliation :(optional)
|
Ophthalmic research center, shahid beheshti university of medical science
|
|
E mail:
|
ramin.retin@gmail.com
|
|
Phone:
|
04413365316
|
|
Mobile:
|
09128249332
|
|
|
|
|
Purpose:
|
To compare the efficacy of combined intravitreal bevacizumab and fasudil (IVB/IVF) with that of IVB alone for diabetic macular edema (DME).
|
|
Methods:
|
In this double masked randomized clinical trial study, 42 eyes with center involving DME were randomized to the two groups. The combined group (IVB/IVF) received 3 monthly injections of IVB (1.25 mg) and IVF (50 µM/L), while the IVB group received 3 monthly IVB (1.25 mg) injections. Findings of the best corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between the two groups at 3 and 6 months of follow up.
|
|
Results:
|
Mean baseline CMT in the IVB/IVF group was 543±102μm which was decreased to 373±100μm and 356±119μm at months 3 and 6, respectively (P<0.001, for both times). Corresponding figures for the IVB group were 511±96μm, 439±112μm (P<0.001) and 509±120μm (P=0.738). CMT reduction was observed in both groups at month 3, but persisted up to 6 months only in the IVB/IVF group. CMT reduction was significantly greater in the IVB/IVF group at both time points (P<0.001). BCVA changes were consistent with CMT changes.
|
|
Conclusion:
|
Adjunctive intravitreal injection of a Rho-kinase inhibitor seems to enhance and prolong the effect of bevacizumab for DME.
|
|
Attachment:
|
|
|
|